Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin Extension Study in Type 2 Diabetes
NCT00881530Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2009
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 2, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Hypoglycaemic Events at 79 weeks, Change From Baseline to Week 78 in Lipid Parameters and 1 more. Started Mar 2009; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00881530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881530.